Novavax, Inc.

$42.30 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Novavax, Inc.

Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Stock Analysis

last close $42.3
1-mo return -22.3%
3-mo return -18.5%
avg daily vol. 6.34M
52-week high 277.8
52-week low 34.88
market cap. $3.2B
forward pe 4.8
annual div. -
roe -898%
ltg forecast -
dividend yield -
annual rev. $1.3B
inst own. 43.1%
baraka

Subscribe now for daily local and international financial news

Subscribe